Aptose Biosciences (NASDAQ:APTO) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTOGet Rating) (TSE:APS) in a research note issued on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, Cantor Fitzgerald reduced their target price on Aptose Biosciences from $10.00 to $6.00 in a report on Wednesday, August 3rd.

Aptose Biosciences Price Performance

NASDAQ:APTO opened at $0.69 on Monday. Aptose Biosciences has a fifty-two week low of $0.67 and a fifty-two week high of $2.78. The stock’s 50-day moving average is $0.79 and its two-hundred day moving average is $0.97. The stock has a market cap of $63.63 million, a PE ratio of -1.09 and a beta of 1.48.

Aptose Biosciences (NASDAQ:APTOGet Rating) (TSE:APS) last announced its quarterly earnings results on Tuesday, August 2nd. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. On average, equities research analysts anticipate that Aptose Biosciences will post -0.49 earnings per share for the current year.

Institutional Trading of Aptose Biosciences

A number of large investors have recently bought and sold shares of the stock. Formidable Asset Management LLC bought a new stake in shares of Aptose Biosciences during the first quarter worth $122,000. Annandale Capital LLC bought a new stake in shares of Aptose Biosciences during the first quarter worth $272,000. Toronto Dominion Bank grew its holdings in shares of Aptose Biosciences by 76.6% during the first quarter. Toronto Dominion Bank now owns 50,186 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 21,776 shares during the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of Aptose Biosciences during the first quarter worth $27,000. Finally, Voss Capital LLC lifted its stake in shares of Aptose Biosciences by 27.3% during the second quarter. Voss Capital LLC now owns 700,010 shares of the biotechnology company’s stock valued at $519,000 after acquiring an additional 150,010 shares during the period. 27.16% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

(Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Featured Stories

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.